All News

Diabetes is undertreated among inpatients, especially acute care patients, sometimes with devastating results. "Blood glucose levels are too often not treated as intensively as other medical conditions among floor patients," said Almut G. Winterstein, Ph.D., assistant professor of pharmacy health care administration at the University of Florida College of Pharmacy. "If hospitals made a more aggressive effort, it could save quite a significant number of lives."

Dasatinib (Sprycel, Bristol-Myers Squibb) is a new tyrosine kinase inhibitor for chronic myelogenous leukemia (CML). The Food & Drug Administration approved the drug in June, and now the National Comprehensive Cancer Network (NCCN) has added dasatinib to its CML guidelines.

Drug-eluting stents (DESs) greatly reduce the chances of restenosis, a gradual growth of abnormal cells within the stent. However, the results of a new study reveal that DESs may also put patients at a higher risk for a sudden and potentially fatal thrombosis.

The Food & Drug Administration recently approved fentanyl buccal tablets (Fentora, Cephalon) for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioids for their underlying persistent cancer pain. Fentora is the first and only buccal tablet approved for this indication and is the first tablet formulation of the opioid fentanyl. It is also the first new medication approved for the treatment of breakthrough pain in opioid-tolerant patients with cancer since 1998.

At most large tertiary care hospitals and academic medical centers, around-the-clock pharmacy service is relatively common. But in some small and rural hospitals, 24-hour, seven-day-a-week pharmacy coverage is not economically feasible or practical. How are pharmacy services provided in those facilities? And how do health-system pharmacists feel about a Joint Commission on Accreditation of Healthcare Organizations proposal that would require all hospital pharmacies to provide 24/7 service?

Catalyst Rx ... HealthTrans ... MedImpact ... Navitus Health Solutions.... These pharmacy benefit managers may not be household names yet, but they are shaking up the PBM market.

In 2005, over 3.4 billion prescriptions were filled-a jump of 59% since 1995. This good news comes from the National Association of Chain Drug Stores Foundation's recently released 2006 Chain Pharmacy Industry Profile.

Pharmacists Planning Service Inc. (PPSI) has submitted a citizen's petition to the Food & Drug Administration to regulate the labeling and packaging of acetaminophen/APAP-containing products so that the label states, "Contains acetaminophen. Do not take with any other acetaminophen/ APAP." PPSI is also asking that no more than 50 tablets be sold in a bottle and that the FDA mandate a MedGuide.

Recently, a certified pharmacy technician expressed her frustration when she and her pharmacist were blamed for unprofessional conduct in their telephone transaction with a doctor. The prescriber claimed to be too important to waste her time digging up numbers that the pharmacist needed to fill her patient's prescription. The doctor immodestly identified herself as a well-known and celebrated practitioner. This, apparently, was a good enough reason to refuse the request for her DEA number.

A pharmacy technician from Seattle has created a disposable, single-use tray and spatula to eliminate the risk of cross-contamination during pill counting in pharmacies.

In an extension of cooperation begun earlier this year, health insurance plans and pharmacist groups have created a booklet and a Web site to guide Medicare beneficiaries through choosing a 2007 Part D plan, just as open enrollment is set to begin on Nov. 15.

The long-awaited first dipeptidyl peptidase-4 (DPP-4) inhibitor will soon make its debut. Januvia (sitagliptin), from Merck & Co., has been approved by the Food & Drug Administration as both a monotherapy and an add-on treatment to improve glycemic control in Type 2 diabetes.

The Food & Drug Administration recently approved ciclesonide (Omnaris, Altana Pharma) for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and children 12 years and older.

CVS and Caremark have entered into a definitive merger agreement that would unite the second-largest mail-order prescription company with the No. 2 drugstore chain.